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ABSTRACT
Context: Assessment of response to cardiac resynchronization therapy (CRT) is essential.
Objective: To assess the predictive value of CT-apelin together with NT-proBNP in patients undergoing
CRT.
Methods: Serum CT-apelin and NT-proBNP were measured by ELISA before, and six months after CRT.
Primary endpoint was non-response (<4% increase in LVEF) after six months.
Results: From 81 patients, 15 proved to be non-responders. Six-month CT-apelin was superior com-
pared to NT-proBNP in identifying non-responders by multivariate ROC (CT-apelin: p¼ 0.01, NT-proBNP:
p¼ 0.13) and by logistic regression (CT-apelin: p¼ 0.01, NT-proBNP: p¼ 0.41) analyses.
Conclusion: Six-month CT-apelin might be a valuable novel biomarker in identifying non-responders
to CRT that was superior to NT-proBNP.
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Context
Cardiac resynchronization therapy (CRT) improves left ven-
tricular function, reduces symptoms and all-cause mortality in
patients with symptomatic systolic heart failure and left bun-
dle branch block (Bristow et al., 2004; Cleland et al., 2005;
Goldenberg et al., 2014; Moss et al., 2009). However, a signifi-
cant number of heart failure patients fail to develop reverse
remodeling after CRT implantation (Goldenberg et al., 2011).
The rate of non-response varies largely depending on the defi-
nitions used (32–91%) (Fornwalt et al., 2010), but non-
responder patients were consistently shown to have signifi-
cantly higher risk for mortality and rehospitalization
(Goldenberg et al., 2011). In order to predict and prevent non-
response, several trials investigated optimal patient selection
and proper risk stratification (Chan et al., 2010; Goldenberg
et al., 2011; Shanks et al., 2011). Based on these, left bundle
branch block (LBBB) morphology and QRS duration seem to
play key roles in success (Zareba et al., 2011). However, it may
be desirable not only to predict, but also to accurately identify
non-responders after CRT. Although echocardiographic con-
trol is still the gold standard to evaluate response to CRT after
3–6 months of implantation, it has a large inter-observer vari-
ability with the need for more objective markers of respon-
siveness (Bellenger et al., 2000; Blondheim et al., 2010).
Biomarkers are often used to obtain prognostic informa-
tion for heart failure patients and to help guiding treatment
during medical management (Maisel, 2011; Maisel &
Choudhary, 2012). NT-proBNP is the gold standard marker to
assess the severity of heart failure, determine prognosis and
tailor medical therapy (Berger et al., 2009; Brenyo et al.,
2013). However, prior studies failed to confirm its role as an
independent predictor of response to CRT (Anand et al.,
2003; Masson et al., 2008).
Apelin, the endogenous ligand for the G protein-coupled
apelin receptor, is emerging as an important regulator of the
cardiovascular homeostasis (O'Carroll et al., 2013). The 77-
amino acid preproapelin is cleaved to shorter peptides, such
as apelin-36, apelin-17, apelin-13, apelin-12, and the post-
translationally modified (Pyr1)apelin-13. These C-terminal ape-
lin fragments (CT-apelin) are all agonists of the apelin
receptor, but binding affinity and biological efficacy differ
from isoform to isoform. In line with the abundant expression
of apelin and its cognate receptor throughout the cardiovas-
cular system, the peptide is a major autocrine/paracrine regu-
lator of vascular tone (O'Carroll et al., 2013), volume
regulation, myocardial contractility and glucose–lipid metab-
olism (Ashley et al., 2005; Farkasfalvi et al., 2007; Japp &
Newby, 2008; Perjes et al., 2014; Szokodi et al., 2002).
Moreover, apelin induces endothelium-dependent
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vasodilation on both arterial and venous side of the circula-
tion (Tatemoto et al., 2001), thereby reducing cardiac preload
and afterload in vivo (Ashley et al., 2005). The beneficial
hemodynamic effects of the peptide are preserved in experi-
mental (Berry et al., 2004) and human chronic heart failure
(Barnes et al., 2013; Japp et al., 2010), which is reflected also
in a direct anti-remodeling effect, in reduced cardiac hyper-
trophy versus interstitial fibrosis, and promoted neo-angio-
genesis (Kuba et al., 2007; Siddiquee et al., 2011; Wang et al.,
2013). Moreover one of the most potent endogenous posi-
tive inotropic agent (Perjes et al., 2014).
However, the role of apelin in heart failure is still unclear
as changes of plasma levels are controversial in humans dur-
ing the progression of heart failure (Chen et al., 2003; Chong
et al., 2006; Foldes et al., 2003; Miettinen et al., 2007). In add-
ition, no data is available on its value in predicting or evalu-
ating the response to CRT. Therefore, we aimed to determine
the clinical value of CT-apelin and NT-proBNP in identifying
non-responders after CRT.
Objectives
Patient recruitment and follow-up:
A single-center, prospective, observational, cohort study
was performed in patients undergoing CRT due to severe
chronic systolic heart failure. In line with current practice
guidelines, inclusion criteria included ejection fraction under
35%, prolonged QRS duration (LBBB: QRS >120ms, non-
LBBB: QRS >150ms) and symptoms of heart failure (NYHA
II–IVa functional class) despite optimal pharmacological treat-
ment (Brignole et al., 2013). Exclusion criteria included
severely reduced life expectancy (<1 year), active malignant
state and complications or failures during CRT implantation.
In addition, patients died before the first follow-up visit at
six months were also censored due to the lack of ability to
classify them according to response criteria. During CRT, sep-
tal (right ventricular lead) and posterolateral/lateral (left ven-
tricular lead) positions were preferred to reach a higher
responder rate.
Detailed laboratory, echocardiographic and physical
examinations were performed at the time of implantation
and six months after CRT. Beyond regular outpatient visits,
patients were contacted via telephone to obtain vital infor-
mation at three years after CRT implantation. In addition, a
national database of vital records was used to track fatal
events (Figure 1). Prior to utilization in our database all rele-
vant patient data was anonymized and encoded. The study
was approved by the Institutional Scientific Ethics Committee
and all patients provided written inform consents for
enrolment.
Screening 
Sept 2009 –Dec 2010: HF patients with NYHA class II-IVa and 
severely reduced EF (<35%) with a QRS > 120 ms were referred for 
CRT
Baseline visit 
Laboratory tests – serum sample collection  
Physical examination, Echocardiography 
Pacemaker implantation 
125 patients underwent successful CRT-P/D implantation 
6 months-follow up: available in 81 patients 
Laboratory tests – serum sample collection  
CT-apelin results were available in 50 patients 
 NT-proBNP in 76 patients
3 year-follow up: no lost to follow-up 
All-cause mortality 
Echocardiography 
Non-responder: 15 patients 
(<4% absolute increase in EF)
Responder: 66 patients 
( 4% absolute increase in EF)
- 10 Patients died 
within 6 months  
- 34 patients with no  
follow-up echo, or 
NT-proBNP or CT-
apelin available 
Figure 1. Flowchart of patient enrollment and follow up.
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Materials and methods
Endpoints
The primary endpoint of the study was non-response to CRT
defined as an absolute increase of less than 4% in ejection
fraction (Rickard et al., 2014) at six months, compared to
baseline measurements. Key secondary endpoint included
all-cause mortality during three years follow-up.
Biomarker measurements
Human CT-apelin was measured by using C-terminus Enzyme
Immunoassay competitive ELISA method (RayBiotech, Inc.,
Norcross, GA) which is designed to target the C-terminus of
the 77-aa apelin peptide. The test detects all active forms of
apelin fragments including apelin-13, -31, -28 and apelin-36.
NT-proBNP was measured with Cobas proBNP II kit (Roche
Diagnostics Gmbh, Mannheim, Germany). Samples were col-
lected at baseline and 6 months after CRT. Serum samples
were stored at 80 C after collection and were assayed later
when sample collection was completed.
Echocardiography
Detailed echocardiographic measurements were performed
both at baseline and 6 months after CRT. To exclude inter-
observer variability, ejection fraction was assessed with
biplane Simpson method by the same experienced investiga-
tor at both time points (Philips iE33 system, Philips
Healthcare, Best, The Netherlands).
Statistical analysis
Continuous variables with normal distributions are expressed
as mean± SD, while those with non-normal distributions as
medians with interquartile range (IQR). Categorical variables
are summarized with frequencies and percentages (n, %).
Baseline clinical characteristics were compared between the
responder and non-responder groups using unpaired t-test
for normally distributed continuous variables, the Mann–
Whitney for non-normally distributed variables, while v2-test
or Fisher exact test was used for dichotomous variables, as
appropriate. Univariate and multivariable receiver-operator
characteristic (ROC) curve analyses were used to determine
the discriminatory capacity of CT-apelin and NT-proBNP on
non-response after CRT. First, univariate ROC test was used
to determine the area under curve (AUC) and p values. In
case of a significant p value, an optimal cutoff was deter-
mined for the continuous variable based on maximal sensitiv-
ity and specificity that best discriminated between responder
and non-responder patients. Using these cutoffs, patients
were separated to low and high biomarker level groups for
logistic regression analyses. Multivariate logistic regressions
were performed with variables showing a p value less than
0.05 in univariate analyses. Time-to-event data is presented
by Kaplan–Meier curves. Event rates represent Kaplan–Meier
estimates. Unadjusted hazard ratios (HR) with 95 confidence
intervals (95%CI) were determined for mortality in Cox
proportional hazards models. Adjusted HR was calculated in
forward stepwise Cox proportional model, including known
predictors of responsiveness and/or mortality after CRT (such
as age, QRS duration, LBBB morphology, female gender,
ischemic etiology). A two-sided p value of <0.05 was consid-
ered statistically significant. Analyses were carried out with
Graph Pad 6.0 and SPSS v9 (SPSS Inc., Chicago, IL).
Results
Baseline patient characteristics
Between September 2009 and December 2010, 81 patients
underwent successful CRT implantation and were included in
the study. Mean age of recruited patients was 64.9 ± 10.5
years, with a mean ejection fraction of 28.5 ± 6.5%. Seventy-
five percent of the patients were in NYHA class III functional
state and 59% had ischemic etiology before CRT implantation
(Table 1).
Response and prognosis
During the mean follow-up of 795 days, seven (9%) patients
died. Based on the pre-defined classification of response, 15
(18.5%) patients proved to be non-responders. Baseline clin-
ical characteristics, medical therapy and echocardiographic
findings were similar between responders and non-respond-
ers (Tables 2 and 3). In line with the definition of response,
left ventricular volumes significantly decreased (ESV: 179.1 ±
64.9 versus 117.9 ± 58.9, p< 0.0001, EDV: 248.6 ± 80.2 versus
196.7 ± 77.5, p< 0.0001) and left ventricular function signifi-
cantly improved (EF: 28.1 ± 6.0 versus 41.3 ± 7.9) in responder
patients after CRT implantation (Tables 2), while these param-
eters remained unchanged in the non-responder group.
(Tables 2) According to Cox-regression analysis, non-respond-
ers had an almost four-fold higher risk for mortality com-
pared with responders (HR: 3.75; 95%CI: 1.00–13.97;
p¼ 0.049) (Figure 2).
This impact on mortality persisted also in the
multivariate model, with non-response to CRT prevailing as
an independent predictor of mortality (adjusted HR: 4.54,
95%CI: 1.14–18.15, p¼ 0.03).
Biomarkers to identify non-responders
At baseline, serum CT-apelin and NT-proBNP levels were simi-
lar in both responders and non-responder patients (p¼ 0.74)
(Table 1) and ROC testing showed that these parameters are
not predictors of non-response (apelin: AUC 0.48; 95%CI:
0.29–0.70; p¼ 0.87, NT-proBNP: AUC 0.53; 95%CI: 0.37–0.70;
p¼ 0.73).
At six months, serum CT-apelin significantly decreased
in responders (from 549.5 ng/ml [IQR: 279.0–868.8] to
211.0 ng/ml [IQR: 113.8–416.8]; p< 0.0001), while it remained
unchanged in non-responder patients (from 472.5 ng/ml [IQR:
307.8–700.3] to 541.0 ng/ml [IQR: 278.3–831.0]; p¼ 0.80)
(Figure 3). Similarly, NT-proBNP levels significantly decreased
in responders at six months (median: 2561 pg/ml, IQR: 1173–
4616 to 1253 pg/ml, IQR: 516–2519; p¼ 0.007), while it
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Table 3. Changes in serum peptide levels between responder and non-responder patients after CRT implantation.
Responder patients Baseline Follow up p value
CT-apelin (ng/ml, med, IQR) 549.5 (279.0/868.8) 211.0 (113.8/416.8) <0.0001***
NT-proBNP (pg/ml, med, IQR) 2561 (1173/4616) 1253 (516/2519) 0.007***
Non-responder patients
CT-apelin (ng/ml, med, IQR) 472.5 (307.8/700.3) 541.0 (278.3/831.0) 0.80
NT-proBNP (pg/ml, med, IQR) 3126 (1238/4492) 2676 (1947/4354) 0.91
p< 0.001.
Table 1. Baseline clinical variables, prior medical history, echocardiographic measurements, serum peptides and medical therapy in the responder and non-
responder patients.
Baseline clinical variables All patients (n¼ 81) Responders (n¼ 66) Non-responders (n¼ 15) p Value
Age (years, mean ± SD) 64.9 ± 10.49 64.1 ± 10.8 68.5 ± 8.4 0.14
Gender (female, n, %) 15 (18.5%) 14 (21%) 1 (7%) 0.28
Ischemic etiology (n, %) 48 (59%) 39 (59%) 9 (60%) 1.00
NYHA II. st (n, %) 11 (14%) 9 (14%) 2 (13%) 1.00
NYHA III. st (n, %) 61 (75%) 49 (74%) 12 (80%) 0.75
NYHA IV. st (n, %) 9 (11%) 8 (12%) 1 (7%) 1.00
QRS (ms, mean ± SD) 167.7 ± 29.8 166.6 ± 28.8 172.0 ± 34.3 0.53
Typical LBBB morphology (n, %) 70 (86%) 57 (86%) 13 (87%) 1.00
Not typical LBBB (n, %) 11 (14%) 9 (14%) 2 (13%) 1.00
6minutes walk test (m, mean ± SD) 311.4 ± 117.1 307.3 ± 127.6 329.2 ± 54.1 0.56
RR systolic (mmHg, mean± SD) 120.4 ± 18.8 121.1 ± 17.4 117.5 ± 24.8 0.51
RR diastolic (mmHg, mean ± SD) 76.2 ± 10.7 76.9 ± 10.2 73.1 ± 12.3 0.21
Heart rate (min1, mean ± SD) 75.6 ± 14.5 75.6 ± 14.1 75.3 ± 16.5 0.93
Atrial fibrillation (n, %) 20 (25%) 14 (21%) 6 (40%) 0.18
Body mass index (BMI; med, IQR) 27.0 (24/30) 27.0 (24/30) 29.0 (26/31) 0.16
Medical history
Hypertension (n, %) 63 (78%) 51 (77%) 12 (80%) 1.00
Type 2 DM (n, %) 25 (31%) 22 (33%) 3 (20%) 0.37
Prior PCI (n, %) 25 (31%) 20 (30%) 5 (33%) 1.00
Prior CABG (n, %) 14 (17%) 11 (17%) 3 (20%) 0.72
Prior stroke (n, %) 8 (10%) 6 (9%) 2 (13%) 0.64
Prior COPD (n, %) 10 (12%) 8 (12%) 2 (13%) 1.00
Prior dyslipidaemia (n, %) 28 (35%) 20 (30%) 8 (53%) 0.13
Prior major arrhythmia – VF (n, %) 3 (4%) 2 (3%) 1 (7%) 0.46
Prior ICD implantation (n, %) 7 (9%) 4 (6%) 3 (20%) 0.11
Echocardiographic parameters
LV ejection fraction (Simpson%, mean ± SD) 28.5 ± 6.5 28.1 ± 6.0 30.4 ± 8.2 0.23
LV end-systolic volume (ml, mean ± SD) 183.5 ± 63.3 179.1 ± 64.9 203.0 ± 51.5 0.22
LV end-diastolic volume (ml, mean ± SD) 254.7 ± 79.1 248.6 ± 80.2 281.5 ± 67.9 0.18
Serum peptides
NT-proBNP (pg/ml; med, IQR) 2573 (1207/4611) 2561 (1173/4616) 3126 (1238/4492) 0.61
CT-apelin (ng/ml; med, IQR) 512.0 (288.3/808.8) 549.5 (279.0/868.8) 472.5 (307.8/700.3) 0.74
Baseline medical therapy (n, %)
Beta blocker (n, %) 74 (91%) 60 (91%) 14 (93%) 1.00
ACE inhibitor or ARB (n, %) 77 (95%) 63 (96%) 14 (93%) 0.57
Spironolactone (n, %) 56 (69%) 46 (70%) 10 (67%) 1.00
Eplerenone (n, %) 7 (9%) 5 (8%) 2 (13%) 0.61
Furosemide (n, %) 62 (77%) 49 (74%) 13 (87%) 0.50
Hydrochlorotiazide (n, %) 9 (11%) 7 (11%) 2 (13%) 0.67
Hydralazine (n, %) 5 (6%) 4 (6%) 1 (7%) 1.00
Digoxin (n, %) 23 (28%) 20 (30%) 3 (20%) 0.54
Amiodarone (n, %) 23 (28%) 19 (29%) 4 (27%) 1.00
Statin (n, %) 50 (62%) 38 (58%) 12 (80%) 0.15
Aspirin (n, %) 38 (47%) 34 (52%) 4 (27%) 0.10
Clopidogrel (n, %) 20 (25%) 17 (26%) 3 (20%) 0.75
Oral anticoagulant therapy (n, %) 26 (32%) 19 (29%) 7 (47%) 0.22
LBBB: left bundle branch block; COPD: chronic obstructive pulmonary disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting;
VF: ventricular fibrillation; ACE: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.
Table 2. Changes in echocardiographic parameters compared to baseline six months after CRT.
Responder patients Baseline Follow up p value
LV ejection fraction (Simpson%, mean± SD) 28.1 ± 6.0 41.3 ± 7.9 <0.0001***
LV end-systolic volume (ml, mean ± SD) 179.1 ± 64.9 117.9 ± 58.9 <0.0001***
LV end-diastolic volume (ml, mean ± SD) 248.6 ± 80.2 196.7 ± 77.5 <0.0001**
Non-responder patients
LV ejection fraction (Simpson%, mean± SD) 30.4 ± 8.2 29.3 ± 7.1 0.34
LV end-systolic volume (ml, mean ± SD) 203.0 ± 51.5 194.8 ± 46.9 0.38
LV end-diastolic volume (ml, mean ± SD) 281.5 ± 67.9 271.6 ± 56.1 0.43
p< 0.01, p< 0.001.
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remained unchanged in non-responder patients (median:
3126 pg/ml [IQR: 1238–4492] to 2676 pg/ml [IQR: 1947–4354];
p¼ 0.91).
In ROC analysis, both six-month CT-apelin and NT-proBNP
levels significantly discriminated between responder and
non-responder patients (CT-apelin: AUC 0.78; 95%CI: 0.59–
0.97; p< 0.01, NT-proBNP: AUC 0.75; 95%CI: 0.62–0.88;
p¼ 0.005). According to the highest sensitivity and specificity,
the optimal cutoffs to diagnose non-response were 268.5 ng/
ml for CT-apelin and 1348.5 pg/ml for NT-proBNP,
respectively.
When patients were classified into groups according to
optimal cutoff values, patients with high serum CT-apelin
showed a 10 times higher odds for non-response (OR: 10.3,
95%CI: 1.16–91.43; p¼ 0.04), while higher NT-proBNP levels
indicated a 16-fold odds for non-response in our patient
cohort (OR: 16.0, 95%CI: 1.96–130.68; p¼ 0.01).
However, multivariate ROC testing suggested the superior-
ity of CT-apelin over NT-proBNP (CT-apelin: AUC 0.78; 95%CI:
0.59–0.97; p¼ 0.013 versus NT-proBNP: AUC 0.67; 95%CI:
0.49–0.85; p¼ 0.13, Figure 4) that was also confirmed in
multivariate logistic regression analysis (CT-apelin: p¼ 0.01,
NT-proBNP: p¼ 0.41).
Discussion
Main findings of our study can be summarized as follows:
1. Our results confirm that a significant group of heart fail-
ure patients (19% in the current cohort) do not develop
reverse remodeling and become non-responders to CRT,
showing an elevated risk for mortality compared to
good responders.
Figure 2. All-cause mortality in responder and non-responder patients to CRT.
Figure 3. Changes in CT-apelin and NT-proBNP levels according to response to CRT.
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2. Baseline levels of CT-apelin and NT-proBNP are not asso-
ciated with non-response. Therefore, neither biomarkers
may be considered as predictors of success before device
implantation.
3. Six-month levels of both CT-apelin and NT-proBNP were
in significant association with non-response, suggesting
the possible role of such biomarkers in identifying non-
responders. Based on multivariate models, our results
suggest the superiority of CT-apelin over NT-proBNP.
These biomarkers may give additional help and informa-
tion to define responder status after CRT, that is in many
times complicated by significant inter-observer variability
of echocardiographic assessment.
CRT improves exercise capacity and reduces the risk of
heart failure events that may all contribute to an improved
event-free survival (Bristow et al., 2004; Cleland et al., 2005;
Moss et al., 2009). However, approximately 20–40% of
patients fail to develop reverse remodeling and are consid-
ered non-responders to treatment (Goldenberg et al., 2011).
As such patients have in average 2–5-fold higher hazard for
all-cause mortality (Goldenberg et al., 2014; Hsu et al., 2012)
and heart failure events, it would be desirable to accurately
identify them during follow-up.
Although NT-proBNP is a valuable biomarker to diagnose
patients with heart failure and stratify them into risk catego-
ries (Hartmann et al., 2004; Masson et al., 2008), data is con-
troversial on its possible role in evaluating the response to
CRT (Brenyo et al., 2013) especially in patients with mildly
symptomatic heart failure. Thus, we aimed to assess the pre-
dictive role of baseline NT-proBNP and the diagnostic value
of six-month follow-up levels in identifying non-responder
patients to CRT.
In our patient cohort, baseline levels were similar in res-
ponders and non-responders, but six-month NT-proBNP lev-
els significantly decreased in responders to CRT. In line with
the biomarker data, responders showed clear echocardio-
graphic evidence of reverse remodeling (Table 2). Similar
results were found in CARE-HF trial (Fruhwald et al., 2007),
where Fruhwald et al. demonstrated that CRT significantly
reduces NT-proBNP levels after 3–6 months compared to
optimal pharmacological treatment. The MADIT-CRT trial also
suggested that baseline serum levels of NT-proBNP were not
related to non-response and to echocardiographic improve-
ments; however, follow-up levels of NT-proBNP were in sig-
nificant association with the echocardiographic response to
resynchronization (Brenyo et al., 2013).
In addition to NT-proBNP, a recently identified cardiac
peptide, apelin has attracted considerable attention in
heart failure. Although changes in plasma apelin levels dur-
ing the progression of heart failure, clinical trials are contro-
versial. In one of the largest studies including 202 patients
Chong et al. found that plasma apelin-12 (also cross-reactive
with apelin-13, -36 fragments) was significantly lower in
patients with advanced heart failure referred for heart trans-
plantation (Chong et al., 2006). In another study Chen et al.
examined 80 patients with moderate to severe chronic
heart failure compared to healthy volunteers. According to
their findings, circulating apelin increases in the early stage,
while in advanced heart failure it decreases to a lower level,
but remains over the normal plasma range (Chen et al.,
2003).
However, the role of apelin in patients after CRT is not
well elucidated. To date, the only small-sized study which
described changes in levels of apelin after CRT was published
by Francia et al. (2007). In 14 patients undergoing device
implantation, significant increase in serum apelin levels was
found after nine months of resynchronization. Evidently, this
low sample size did not allow the authors to compare apelin
in responder and non-responder patients; the single patient
considered non-responder had higher apelin level than the
others.
In our patient cohort including 81 patients, responders
and non-responders showed the same CT-apelin values at
baseline. However, non-responders had significantly higher
CT-apelin levels at six months compared to responders after
CRT implantation. Likewise, patients with high CT-apelin
levels had a 10-fold higher risk for non-response.
Given the potential collinearity between NT-proBNP and
apelin, multivariate models were developed to determine the
independent estimate of non-response. Based on such statis-
tical models, apelin proved to be the independent biomarker
in identifying non-response (Figure 4).
These results suggest that a simple measurement of
apelin or NT-proBNP during follow-up of CRT implantation
may help in identifying non-responders to therapy. This
may be of great clinical importance due to the potential
difficulties in judging relatively small absolute changes in
ejection fraction during control echocardiographic meas-
urements, as well as considering the significant inter-
observer variability of the echocardiographic examination
(Bellenger et al., 2000; Blondheim et al., 2010). Our results
suggest that CT-apelin may be the preferred marker for
classification, but further studies are needed to confirm
these findings.
Figure 4. Receiver-operator characteristic curve analysis comparing the diag-
nostic performance of six-month serum CT-apelin and NT-proBNP levels on
identifying non-responders to CRT.
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Conclusions
Non-responders have a significantly elevated risk for mortality
after CRT implantation. Not baseline, but six-month CT-apelin
and NT-proBNP levels were significant indicators of non-
response to CRT. Our results suggest that a simple biomarker
measurement during follow-up may help to identify non-res-
ponders who have poor outcomes after CRT implantation.
Further studies using the same methodology are required to
corroborate these findings in a larger patient population and
to determine whether apelin may be used to alter manage-
ment in patients with severe systolic heart failure.
Limitations
Our study has some certain limitations. First, this was a rela-
tively small registry-based patient cohort with low rate of
endpoint events that may result in overestimating the real
predictive value of both biomarkers. Therefore, the suggested
cutoff values for both biomarkers need to be validated in
larger prospective studies for good and poor responders to
CRT. Moreover, the low sample size might be also a reason
why traditional clinical predictors of responsiveness were not
identified between responders and non-responders. Notably,
this is still the largest dataset among patients after CRT
implantation with apelin level assessments at a relatively
long (three-year) follow-up.
Second, the observed plasma levels of CT-apelin in our
study were considerably higher than found in other prior stud-
ies (Foldes et al., 2003; Miettinen et al., 2007). This may be due
to the various sensitivities of the assays for different apelin
fragments, making it difficult to directly compare results. By
using RayBiotech C-Terminus-apelin ELISA kit we have
detected apelin-36, -13, -28 and -31 fragments, that might be
responsible for the differences compared to other authors
that usually detected only the apelin-12, -13, -36 fragments by
another commercially available ELISA kit (Chen et al., 2003;
Francia et al., 2007; Miettinen et al., 2007). In addition, the
observed plasma apelin levels in the tested individuals were
within the range of the kit provided by the test manufacturer.
Third, although baseline levels of apelin and NT-proBNP
were not in relation with non-response, our results cannot
determine the optimal time of biomarker sampling after CRT.
We have only used six-month biomarker data, but it is pos-
sible that such associations may also exist earlier after device
implantation.
Finally, the three-year rate of cardiovascular mortality may
sound quite low in the present study compared to other
experiences (Bristow et al., 2004; Cleland et al., 2005).
However, we only included patients with successful device
implantation and having six-months biomarker laboratory
results available. Therefore, our results may reflect a lower-
risk cohort with successful device implantation and without
mortality within the first six months of CRT operation.
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